Pegilodeckin, an immunotherapy acquired in the company's $1.6 billion deal for Armo BioSciences, failed to extend survival in patients with pancreatic cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,